# PPP6C

Source: https://onco.cc/targets/ppp6c/  
OnCo record `ppp6c` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PPP6C (Serine/threonine-protein phosphatase 6 catalytic subunit) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Melanoma and Basal cell carcinoma.

## Summary

Catalytic subunit of protein phosphatase 6 (PP6). PP6 is a component of a signalling pathway regulating cell cycle progression in response to IL2 receptor stimulation. N-terminal domain restricts G1 to S phase progression in cancer cells, in part through control of cyclin D1.

Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.84, genetic association 0.00, somatic mutation 0.91). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Basal Cell Carcinoma, Melanoma, Cutaneous Melanoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein phosphatase 6 catalytic subunit; Serine/threonine-protein phosphatase 6 catalytic subunit; PP6
- Tags: cancer-genes-wave
- Symbol: PPP6C
- Class: enzyme
- Biology: Catalytic subunit of protein phosphatase 6 (PP6). PP6 is a component of a signalling pathway regulating cell cycle progression in response to IL2 receptor stimulation. N-terminal domain restricts G1 to S phase progression in cancer cells, in part through control of cyclin D1. During mitosis, regulates spindle positioning. Down-regulates MAP3K7 kinase activation of the IL1 signalling pathway by dephosphorylation of MAP3K7. Also participates in the innate immune defense against viruses by desphosphorylating RIGI, an essential step that triggers RIGI-mediated signalling activation. Location: Mitochondrion; Cytoplasm (UniProt). Locus 9q33.3 (HGNC).
- Where found: Skin cancer: Open Targets association 0.64 with skin cancer (MONDO_0002898); Melanoma: Open Targets association 0.70 with melanoma (MONDO_0005105); IntOGen driver in 4 cohorts (MEL, SKCM); Basal cell carcinoma: IntOGen driver in 1 cohort (BCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9323: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9323
- UniProt O00743: https://www.uniprot.org/uniprotkb/O00743/entry
- NCBI Gene 5537: https://www.ncbi.nlm.nih.gov/gene/5537
- Ensembl ENSG00000119414: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119414

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/ppp6c.json